Pegfilgrastim Biosimilars: Where Are We Now?

Area of Science:

• Hematology
• Pharmacology
• Biotechnology

Background:

• Recombinant methionyl human granulocyte colony-stimulating factor (filgrastim) was approved by the FDA in 1991 for human use.
• Filgrastim significantly impacted neutropenia treatment, with over 1 million patients using it within its first 5 years.
• A modified version, pegfilgrastim, was approved in 2002, offering a longer half-life and single-injection convenience.

Purpose of the Study:

• To review the historical development and standard of care for neutropenia treatment.
• To highlight the regulatory changes that enabled the introduction of biosimilars.
• To inform practitioners about the expanding availability of pegfilgrastim biosimilars.

Main Methods:

• Review of historical FDA approvals and clinical use data for filgrastim and pegfilgrastim.
• Analysis of the impact of the Biologics Price Competition and Innovation Act of 2009.
• Examination of the current market landscape for pegfilgrastim biosimilars.

Main Results:

• Filgrastim and pegfilgrastim established themselves as standard treatments for neutropenia.
• The 2009 act created a pathway for biosimilar approvals, increasing competition.
• A diverse and growing market of pegfilgrastim biosimilars is now available to practitioners.

Conclusions:

• The evolution of G-CSF therapy has provided significant advancements in neutropenia management.
• Regulatory frameworks have successfully fostered the development and accessibility of biosimilar medications.
• Healthcare providers now have a wider array of effective and potentially cost-efficient options for pegfilgrastim treatment.